Navigation Links
Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Date:8/27/2013

nalysis and without the clinical study report for the interim analysis; the potential to accelerate the timing of the review of the Contrave NDA; the safety and effectiveness of Contrave; the potential for past Contrave clinical trials to predict the outcome of future Contrave clinical trials; the SPA and the protocol for the Contrave® cardiovascular outcomes trial, or Light Study; the potential for and timing of a submission of an MAA in the European Union; the potential for approval of the Contrave MAA by the EMA; and the potential to license commercial rights to Contrave outside North America. The inclusion of forward‐looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ materially from those expressed or implied in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the possibility that the FDA determines not to initiate review of the Contrave NDA until it has received the complete study report for the interim analysis; the SPA is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen's ability to conduct the Light Study and the progress and timing thereof, including risks associated with enrolling and retaining the appropriate patients in the Light Study; Orexigen's ability to demonstrate in the Light Study that the risk of MACE in overweight and obese patients treated with Contrave does not adversely affect Contrave's benefit‐risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE data; the potential for th
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... a study published today (August 22nd), in the ... the Champalimaud Neuroscience Programme establish the effect of ... of advanced genetic and optical techniques., "Serotonin is ... a wide range of brain functions, from the ... of complex emotional behaviours, This neurotransmitter is also ...
(Date:8/22/2014)... 2014 Ophthalmic drug delivery technologies ... challenging endeavors as the anatomy, physiology and biochemistry ... the foreign substances. Ocular drug delivery technologies provide ... and minimal use of needles; also it enables ... provides specific targeting within the ocular globe. On ...
(Date:8/22/2014)... -- Research and Markets has announced the ... & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market ... The global molecular biology enzymes market ... expected to grow at a CAGR of 13.74% to ... & reagents find applications in a large number of ...
(Date:8/22/2014)... 22, 2014 The identification of ... can be accelerated by exome sequencing. Built on ... the custom SeqCap EZ Developer system has been ... Watson will additionally present how he achieved coverage ... human and mouse exome kits. With over 236,000 ...
Breaking Biology Technology:From happiness to pain: Understanding serotonin's function 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2
... Update on Key Regulatory Milestones, SEATTLE, Sept. 11 ... MTA: CTIC) announced today that it will host an,investor ... investor day will,provide an update from executive management on ... meeting will be an,invitation-only event. A webcast and live ...
... the Top 100 Businesses in Boston-, Cambridge-Quincy, MA-NH and ranked No. ... ... Observant LLC is pleased to announce,that it has been named one of the ... 1,093 places it in the Top,22% of companies on the list. The list ...
... System Now Available to Nearly 30 Percent of ... ... unparalleled in modern,healthcare, Hoana Medical, Inc. and several Hawai,i unions are ... won,t be covered by insurance companies. Whereas typical,healthcare insurers like Blue ...
Cached Biology Technology:Observant LLC Makes the 2008 Inc. 5000 List 2Observant LLC Makes the 2008 Inc. 5000 List 3Hoana Medical and Hawai'i Union Health and Welfare Trust Funds Partner to Fix Healthcare 2Hoana Medical and Hawai'i Union Health and Welfare Trust Funds Partner to Fix Healthcare 3Hoana Medical and Hawai'i Union Health and Welfare Trust Funds Partner to Fix Healthcare 4Hoana Medical and Hawai'i Union Health and Welfare Trust Funds Partner to Fix Healthcare 5
(Date:8/21/2014)... aimed at improving the food intake, health and quality ... is among three projects at the University of Waterloo ... Canadian Institutes of Health Research (CIHR). , Professor ... at Waterloo, and a Schlegel research chair in nutrition ... investigate why many Canadians living in long-term care homes ...
(Date:8/21/2014)... has implications for life in other extreme environments, both ... LSU Associate Professor of Biological Sciences Brent Christner and ... NSF, this week published a paper confirming that the ... meters (2600 feet) beneath the surface of the West ... more than 400 subglacial lakes and numerous rivers and ...
(Date:8/21/2014)... the water window? It consists of radiations in the ... by the water in biological tissues. New theoretical findings ... within the water window. These could be the basis ... of the biological samples or to be used in ... physical mechanism needed to efficiently generate the harmonic radiationswhich ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4Water window imaging opportunity 2
... similarities between Grenoble and Hollywood or between the researchers ... (IBS) and world-known filmmakers. However, scientists from these institutes ... movie. The actors are not celebrities but a protein ... this protein in action by freezing it at several ...
... that hopes to use a patient's own immune cells to ... a specialty procedure performed in only a handful of institutions, ... , Julian A. Kim, M.D., chief of surgical oncology at ... the National Institutes of Health for a five-year study that ...
... 12 surgeons and 21 surgical residents, video game skill ... a simulated surgery skills course, according to a report ... of the JAMA/Archives journals. , James C. Rosser Jr., ... colleagues asked 33 surgeons (21 residents and 12 attending ...
Cached Biology News:Freeze! Scientists film proteins at work by freezing them at different states 2
... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
... (A) and 36kDa (C) subunits Formulation: ... 500mM NaCl, 60mM 2-mercaptoethanol, 1mM MgCl2, ... and 0.1mg/ml serum albumin Properites: For ... Purification: DEAE chromatography, aminohexyl-agarose and gel ...
... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
Biology Products: